Hoffmann E, Bach P, Haberl R, Mattke S, Steinbeck G
Medizinische Klinik I der Ludwig-Maximilians-Universität, München.
Z Kardiol. 1992 Jul;81(7):378-84.
The efficacy and safety of the new class-I antiarrhythmic drug cibenzoline was assessed in 12 patients with spontaneous and inducible ventricular tachycardia. Programmed ventricular stimulation, 24-h ambulatory electrocardiogram (ECG), and continuous ECG monitoring were performed without antiarrhythmic drugs and after oral administration of 254 +/- 80 mg of the substance. Oral cibenzoline suppressed the induction of tachycardia in only one patient. Induction of tachycardia was more difficult in two patients, unchanged in four patients, and easier in two patients. Cycle length of induced tachycardia and QT-interval corrected for frequency were not changed significantly; effective refractory period of the right ventricle was prolonged. Twenty-four hours of ambulatory monitoring during cibenzoline treatment (n = 9) showed no significant increase in the frequency of ventricular premature complexes. However, spontaneous sustained ventricular tachycardia developed in three patients after initiation of cibenzoline treatment. In two patients, termination of induced ventricular tachycardia was significantly more difficult under cibenzoline; several DC-shocks were required to terminate the tachycardia. Thus, the use of oral cibenzoline in patients with sustained spontaneous and inducible ventricular tachycardias showed a low antiarrhythmic efficacy at programmed stimulation and a high incidence of spontaneous ventricular tachycardia.
在12例伴有自发性和诱发性室性心动过速的患者中评估了新型I类抗心律失常药物西苯唑啉的疗效和安全性。在未使用抗心律失常药物的情况下以及口服254±80mg该药物后，进行了程序心室刺激、24小时动态心电图（ECG）和连续ECG监测。口服西苯唑啉仅在1例患者中抑制了心动过速的诱发。2例患者诱发心动过速变得更加困难，4例患者无变化，2例患者则更容易诱发。诱发心动过速的周期长度和经频率校正的QT间期无显著变化；右心室的有效不应期延长。在西苯唑啉治疗期间（n = 9）进行的24小时动态监测显示室性早搏频率无显著增加。然而，在开始西苯唑啉治疗后，3例患者出现了自发性持续性室性心动过速。在2例患者中，在西苯唑啉作用下，诱发的室性心动过速终止明显更加困难；需要多次直流电电击才能终止心动过速。因此，对于伴有持续性自发性和诱发性室性心动过速的患者，口服西苯唑啉在程序刺激时显示出较低的抗心律失常疗效，且自发性室性心动过速的发生率较高。
